p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
暂无分享,去创建一个
L. Vassilev | A. Hoffbrand | R. Wickremasinghe | A. Prentice | A. Steele | E. Nacheva | S. Hart | P. Kottaridis | K. Cwynarski | V. Duke | Julie Howard-Reeves | B. C. Yogashangary
[1] James M. Roberts,et al. CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .
[2] Earl F. Glynn,et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function , 2008, Nature Medicine.
[3] N. Plesnila,et al. Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-κB transcriptional activity , 2007, Cell Death and Differentiation.
[4] A. Pettitt,et al. The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia , 2007, Leukemia.
[5] K. Vousden,et al. p53: new roles in metabolism. , 2007, Trends in cell biology.
[6] Augusto Silva,et al. Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation , 2007, Apoptosis.
[7] S. Cory,et al. The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.
[8] Erinna F. Lee,et al. Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.
[9] Michael T. Certo,et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.
[10] K. Vousden. Outcomes of p53 activation - spoilt for choice , 2006, Journal of Cell Science.
[11] T. Yamagata,et al. TEL/ETV6 induces apoptosis in 32D cells through p53-dependent pathways. , 2006, Biochemical and biophysical research communications.
[12] Marina Konopleva,et al. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.
[13] L. Zhang,et al. Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis , 2006, Oncogene.
[14] Gabriel Pons,et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.
[15] R. Fanin,et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) , 2006 .
[16] S. Lowe,et al. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. , 2006, Experimental hematology.
[17] Horst Kessler,et al. WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization* , 2006, Journal of Biological Chemistry.
[18] J. Charlot,et al. Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-α on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells , 2006, Apoptosis.
[19] M. Christmann,et al. Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival. , 2005, Cancer research.
[20] David P Lane,et al. p53 isoforms can regulate p53 transcriptional activity. , 2005, Genes & development.
[21] Sudhir V. Shah,et al. p53-dependent Caspase-2 Activation in Mitochondrial Release of Apoptosis-inducing Factor and Its Role in Renal Tubular Epithelial Cell Injury* , 2005, Journal of Biological Chemistry.
[22] T. Kipps,et al. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis. , 2005, Blood.
[23] A. Gudkov,et al. Prospective therapeutic applications of p53 inhibitors. , 2005, Biochemical and biophysical research communications.
[24] L. Greene,et al. Puma and p53 Play Required Roles in Death Evoked in a Cellular Model of Parkinson Disease , 2005, Neurochemical Research.
[25] Marc K Hellerstein,et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.
[26] G. Klein,et al. Wild-type p53 activates SAP expression in lymphoid cells , 2004, Oncogene.
[27] R. Hamdy,et al. Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice , 2004 .
[28] Martin Schuler,et al. Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.
[29] A. Gunasekera,et al. Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR , 2004, FEBS letters.
[30] L. Vassilev,et al. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.
[31] A. Newland,et al. Bax conformational change is a crucial step for PUMA-mediated apoptosis in human leukemia. , 2003, Biochemical and biophysical research communications.
[32] C. Culmsee,et al. Reciprocal Inhibition of p53 and Nuclear Factor-κB Transcriptional Activities Determines Cell Survival or Death in Neurons , 2003, The Journal of Neuroscience.
[33] Dylan T. Jones,et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. , 2003, Blood.
[34] K. Roemer,et al. Inhibition of p53 protects liver tissue against endotoxin‐induced apoptotic and necrotic cell death , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] T. Burns,et al. Microarray Analysis of p53 Target Gene Expression Patterns in the Spleen and Thymus in Response to Ionizing Radiation , 2003, Cancer biology & therapy.
[36] Petr Pancoska,et al. p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.
[37] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[38] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[39] A. Garden,et al. A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[40] K. Ganeshaguru,et al. Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. , 2001, Blood.
[41] A. Pettitt,et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. , 2001, Blood.
[42] J. Vilpo,et al. Pharmacokinetics of chlorambucil in patients with chronic lymphocytic leukaemia: comparison of different days, cycles and doses. , 2000, Pharmacology & toxicology.
[43] M V Chernov,et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. , 1999, Science.
[44] M. Grever,et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.
[45] N. Chiorazzi,et al. mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .
[46] H. Döhner,et al. Efficient nucleofection of primary human B cells and B-CLL cells induces apoptosis, which depends on the microenvironment and on the structure of transfected nucleic acids , 2007, Leukemia.
[47] M. Konopleva,et al. may overcome Atm-mediated resistance to fludarabine in chronic transcription-dependent and transcription-independent mechanisms Mdm 2 inhibitor Nutlin-3 a induces p 53-mediated apoptosis , 2006 .
[48] M. Konopleva,et al. Mdm 2 inhibitor Nutlin-3 a induces p 53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to Fludarabine in chronic lymphocytic leukemia , 2006 .
[49] T. Stankovic,et al. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. , 2004, Blood.
[50] J. Trapani,et al. Assaying cytochrome C translocation during apoptosis. , 2004, Methods in molecular biology.
[51] M. Ramsby,et al. Differential detergent fractionation of eukaryotic cells. Analysis by two-dimensional gel electrophoresis. , 1999, Methods in molecular biology.
[52] A. G. Bosanquet,et al. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. , 1996, Blood.
[53] G. L. Peterson. Determination of total protein. , 1983, Methods in enzymology.
[54] G. L. Peterson. [12] Determination of total protein , 1983 .